Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | LCAT | P04180 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585785 | 1.00 | ADRB2 (0.65) | ADRB2HTR2CCXCR3LCKSRC | |
| SCHEMBL5585596 | 1.00 | ADRB2 (0.65) | ADRB2HTR2CCXCR3LCKSRC | |
| SCHEMBL6204964 | 0.88 | ADRB2 (0.58) | ADRB2HTR2CCXCR3LCKSRC | |
| SCHEMBL29388809 | 0.80 | ADRB2 (0.97) | ADRB2HTR2CCXCR3LCATALDH1A1 | |
| SCHEMBL906077 | 0.80 | ADRB2 (0.97) | ADRB2HTR2CCXCR3LCATALDH1A1 | |
| SCHEMBL5585677 | 0.79 | HTR2C (0.45) | ADRB2HTR2CLCKSRCACVR1 | |
| SCHEMBL5585944 | 0.79 | HTR2C (0.45) | ADRB2HTR2CLCKSRCACVR1 | |
| SCHEMBL5585680 | 0.79 | HTR2C (0.45) | ADRB2HTR2CLCKSRCACVR1 | |
| Hydrochloric Acid SCHEMBL5585896 | 0.79 | ADRB2 (1.00) | ADRB2HTR2CCXCR3LCATALDH1A1 | |
| SCHEMBL5780913 | 0.77 | HTR2C (0.41) | ADRB2HTR2CLCKSRCACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | claimed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | claimed |
| JP-2005529926-A | — | — | 2005-10-06 | — | — | JP | claimed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | claimed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | claimed |
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | ADRB2 63/4885HTR2C 233/4885CXCR3 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.